Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation

Currently only patients with HER2-positive tumors are candidates for HER2-targeted therapies. However, recent clinical observations suggest that the survival of patients with HER2-low breast cancers, who lack HER2 amplification, may benefit from adjuvant therapy that targets HER2. In this study, we...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Lee, Cleo Yi-Fang, Lin, Yuan, Bratman, Scott V., Feng, Weiguo, Kuo, Angera H., Scheeren, Ferenc A., Engreitz, Jesse M., Varma, Sushama, West, Robert B., Diehn, Maximilian
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3917843/
https://ncbi.nlm.nih.gov/pubmed/24177178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1055
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares